172 related articles for article (PubMed ID: 16855979)
21. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
22. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
23. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014.
Whittaker R; Dias JG; Ramliden M; Ködmön C; Economopoulou A; Beer N; Pastore Celentano L;
Vaccine; 2017 Apr; 35(16):2034-2041. PubMed ID: 28314560
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Soriano-Gabarró M; Rosenstein N; LaForce FM
J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
[TBL] [Abstract][Full Text] [Related]
26. Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany.
Wiese-Posselt M; Hellenbrand W; Siedler A; Mayer C
Euro Surveill; 2006 Sep; 11(9):E060907.4. PubMed ID: 17075143
[No Abstract] [Full Text] [Related]
27. The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials.
Voysey M; Sadarangani M; Clutterbuck E; Bolgiano B; Pollard AJ
Vaccine; 2016 Jul; 34(34):3986-92. PubMed ID: 27349840
[TBL] [Abstract][Full Text] [Related]
28. Serogroup B meningococcal vaccines.
Zimmer SM; Stephens DS
Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
[TBL] [Abstract][Full Text] [Related]
29. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
[TBL] [Abstract][Full Text] [Related]
30. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
Hale SF; Camaione L; Lomaestro BM
Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
[TBL] [Abstract][Full Text] [Related]
31. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
32. Towards an improved serogroup B Neisseria meningitidis vaccine.
Perrett KP; Pollard AJ
Expert Opin Biol Ther; 2005 Dec; 5(12):1611-25. PubMed ID: 16318425
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
Findlow H; Borrow R
Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy, safety, and cost-effectiveness of meningococcal vaccines].
Chinese Preventive Medicine Association
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):129-135. PubMed ID: 30744260
[TBL] [Abstract][Full Text] [Related]
35. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
36. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants.
Schmitt HJ; Steul KS; Borkowski A; Ceddia F; Ypma E; Knuf M
Vaccine; 2008 Apr; 26(18):2242-52. PubMed ID: 18407386
[TBL] [Abstract][Full Text] [Related]
37. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
[TBL] [Abstract][Full Text] [Related]
39. Meningococcal polysaccharide-protein conjugate vaccines.
Snape MD; Pollard AJ
Lancet Infect Dis; 2005 Jan; 5(1):21-30. PubMed ID: 15620558
[TBL] [Abstract][Full Text] [Related]
40. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
